ADC Therapeutics SA
NYSE:ADCT

Watchlist Manager
ADC Therapeutics SA Logo
ADC Therapeutics SA
NYSE:ADCT
Watchlist
Price: 2.03 USD 3.57%
Market Cap: 196.3m USD
Have any thoughts about
ADC Therapeutics SA?
Write Note

ADC Therapeutics SA
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ADC Therapeutics SA
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
ADC Therapeutics SA
NYSE:ADCT
Income from Continuing Operations
-$234.5m
CAGR 3-Years
2%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
Income from Continuing Operations
-CHf39.9m
CAGR 3-Years
18%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Income from Continuing Operations
-$239.6m
CAGR 3-Years
N/A
CAGR 5-Years
-84%
CAGR 10-Years
N/A
Molecular Partners AG
SIX:MOLN
Income from Continuing Operations
-CHf69.1m
CAGR 3-Years
1%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Income from Continuing Operations
-CHf652k
CAGR 3-Years
76%
CAGR 5-Years
51%
CAGR 10-Years
33%
Kuros Biosciences AG
SIX:KURN
Income from Continuing Operations
-CHf8.9m
CAGR 3-Years
-15%
CAGR 5-Years
5%
CAGR 10-Years
N/A
No Stocks Found

ADC Therapeutics SA
Glance View

Market Cap
196.3m USD
Industry
Biotechnology

ADC Therapeutics SA is a clinical-stage biotechnology company. The company is headquartered in Epalinges, Vaud and currently employs 312 full-time employees. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.

ADCT Intrinsic Value
4.99 USD
Undervaluation 59%
Intrinsic Value
Price

See Also

What is ADC Therapeutics SA's Income from Continuing Operations?
Income from Continuing Operations
-234.5m USD

Based on the financial report for Dec 31, 2023, ADC Therapeutics SA's Income from Continuing Operations amounts to -234.5m USD.

What is ADC Therapeutics SA's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-14%

Over the last year, the Income from Continuing Operations growth was -51%. The average annual Income from Continuing Operations growth rates for ADC Therapeutics SA have been 2% over the past three years , -14% over the past five years .

Back to Top